Intelligently
mining the market

Investors + news

We’re creating unmatched value through enhanced treatments and valued partnerships. And with an estimated $3.4 billion in annual brand sales, we believe we’re just getting started on our mission to maximize the full potential of treatments for patients and physicians around the globe.

see our business strategy in action

Eagle Pharmaceuticals 2021 Annual Report

Investors Menu

Investors

Featured Press Release

-- ENA-001, with a novel mechanism of action as an agnostic respiratory stimulant, has previously been granted Rare Pediatric Disease Designation for the treatment of Apnea of Prematurity by the FDA with eligibility for a priority review voucher -- -- The compound is also being developed for
See More
-- ENA-001, a new chemical entity with a unique mechanism of action, is being developed as an agnostic respiratory stimulant for use in multiple patient populations experiencing acute respiratory depression -- -- Development is under way of intramuscular formulation for treatment of community drug
See More
WOODCLIFF LAKE, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the Morgan Stanley 20 th Annual Global
See More

Upcoming Events & Presentations

No items found.

Change % Volume Data as of 09/10/2022 6:42 AM EDT Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor Contact

In-Site
Communications, Inc.
Lisa M. Wilson,
212-452-2793

For all other media inquiries, please contact us.